

# THE NEW ENGLAND DRUG METABOLISM DISCUSSION GROUP

Charles L. Crespi (Chair)  
Corning Life Sciences  
[crespic@corning.com](mailto:crespic@corning.com)

Hanlan Liu (Chair elect)  
Catabasis  
[hliu@catabasis.com](mailto:hliu@catabasis.com)

Stephen Wang (Treasurer)  
Pfizer  
[Stephen.Wang@Pfizer.com](mailto:Stephen.Wang@Pfizer.com)

Sirimas Sudsakorn  
(Secretary/Communications)  
Sanofi  
[Sirimas.Sudsakorn@sanofi.com](mailto:Sirimas.Sudsakorn@sanofi.com)

Upendra Argikar  
Novartis  
[upendra.argikar@novartis.com](mailto:upendra.argikar@novartis.com)

Rieko Arimoto  
Vertex Pharmaceuticals  
[rieko\\_arimoto@vrtx.com](mailto:rieko_arimoto@vrtx.com)

Tonika Bohnert  
Biogen  
[tonika.bohnert@biogen.com](mailto:tonika.bohnert@biogen.com)

Tom Chan  
Boehringer-Ingelheim  
[Tom.chan@boehringer-ingelheim.com](mailto:Tom.chan@boehringer-ingelheim.com)

E. Radford Decker  
Sunovion  
[Radford.Decker@sunovion.com](mailto:Radford.Decker@sunovion.com)

Adrian Fretland  
AstraZeneca  
[Adrian.fretland@astrazeneca.com](mailto:Adrian.fretland@astrazeneca.com)

Dean Hickman  
Amgen  
[deanh@amgen.com](mailto:deanh@amgen.com)

Franco Lombardo  
Alkermes  
[Franco.Lombardo@alkermes.com](mailto:Franco.Lombardo@alkermes.com)

Chandra Prakash  
AgiOS  
[chandra.prakash@agios.com](mailto:chandra.prakash@agios.com)

Haojing Rong  
Shire  
[hrong@shire.com](mailto:hrong@shire.com)

Wen Chyi Shyu  
Takeda Pharmaceuticals  
[WenChyi.Shyu@takeda.com](mailto:WenChyi.Shyu@takeda.com)

David J. Waxman  
Boston University  
[djw@bu.edu](mailto:djw@bu.edu)

Nancy Wong  
Alexion Pharmaceuticals, Inc.  
[nancy.wong@alexion.com](mailto:nancy.wong@alexion.com)

Zhiyang Zhao  
Alliance Pharma  
[zzhao@alliancepharmaco.com](mailto:zzhao@alliancepharmaco.com)

Hello -

Our NEDMDG Spring Meeting will be held on **Wednesday, March 7<sup>th</sup>, 2018** at *Pfizer Research Technology Center, 1 PORTLAND STREET, CAMBRIDGE, MA 02139*

***This Meeting is Sponsored by:***



**In Vitro ADMET Laboratories, Inc. (IVAL)**  
Columbia, MD USA

***Entitled:***

**"Mutant IDH1 inhibitor ivosidenib: from patient to bench to clinic"**

***Speaker:***

***Scott Biller, Ph.D.***  
***Chief Scientific Officer***

AgiOS Pharmaceuticals, Inc

The cocktail hour will begin at 5:30 PM, dinner at 6:30 PM and the presentation at 7:30 PM.

***If you need a 'Special Food Request' contact:***  
***[Sirimas.sudsakorn@sanofi.com](mailto:Sirimas.sudsakorn@sanofi.com)***

**\*\*\*\*\*The deadline for reservations or cancellations is 4pm, March 2<sup>nd</sup>, 2018\*\*\*\*\***

**\*\*\*\*\*NO WALK-IN OR LATE REGISTRATION ACCEPTED\*\*\*\*\***

The link for easy registration is:

<https://www.events.org/nedmdg01/viewevent.aspx?id=114912>